06/02/2016 | 02:31pm CEST
The data demonstrates the safety and efficacy of the company's proprietary ISC-hpNSC® readily expandable neural stem cell derived treatment of Parkinson's disease.
"The publication of the data in the peer-reviewed and highly-respected journal, Cell Transplantation, brings to conclusion the preclinical stage of ISCO's Parkinson's disease program. The data provides further evidence that parthenogenetic neural stem cells can be effective in treating the symptoms of Parkinson's disease and, along with the previously safety data, formed the basis of our application to the Australian regulatory authorities to move this program into the clinic," said Russell Kern , Ph.D., ISCO's Chief Scientific Officer.
The 12-month GLP study demonstrated the safety and efficacy of transplanting ISC-hpNSC® into non-human primates with induced moderate to severe clinical Parkinson's disease symptoms. Transplantation of neural cells was safe and well tolerated by the animals with no dyskinesia, tumors, ectopic tissue formation or other test article related serious adverse events.
It was shown that ISC-hpNSC® improved Parkinson's disease symptoms by increasing the number of dopaminergic neurons and dopamine concentration in the brain through neurotrophic support and dopamine neuron replacement. This data from this study was closely reviewed by the Australian Therapeutic Goods Administration (TGA) and supported the clinical trial approval of ISC-hpNSC® for the treatment of Parkinson's disease (ClinialTrials.gov NCT02452723).
The article and abstract can be found at:
http://www.ingentaconnect.com/content/cog/ct/pre-prints/content-CT-1518_Gonzalez_et_al
About the Parkinson's disease clinical study
The Phase I clinical study is a dose escalation safety and preliminary efficacy study of ISC-hpNSC® , intracranialy transplanted into patients with moderate to severe Parkinson's disease. The open-label, single center, uncontrolled clinical trial will evaluate three different dose regimens. A total of 12 participants with moderate to severe Parkinson's disease will be treated. Following transplantation, the patients will be monitored for 12 months at specified intervals, to evaluate the safety and biologic activity of ISC-hpNSC®. PET scans will be performed at baseline, as part of the screening assessment, and at 6 and 12 months after surgical intervention. Clinical responses compared to baseline after the administration of ISC-hpNSC® will be evaluated using various neurological assessments such as Unified Parkinson Disease Rating Scale (UPDRS), Hoehn and Yahr and other rating scales.
The study will be performed at Royal Melbourne Hospital in Australia . The study's submission is overseen by ISCO subsidiary, Cyto Therapeutics Pty Ltd.
About Parkinson's disease
Parkinson's disease (PD) is a degenerative disorder of the central nervous system mainly affecting the motor system. The motor symptoms of Parkinson's disease result from the death of dopamine-generating cells in the substantia nigra, a region of the midbrain. Early in the course of the disease, the most obvious symptoms are movement-related; these symptoms include shaking, rigidity, slowness of movement and difficulty with walking and gait. Later, thinking and behavioral problems may arise, with dementia commonly occurring in the advanced stages of the disease, and depression is the most common psychiatric symptom. Parkinson's disease is more common in older people, with most cases occurring after the age of 50.
Currently, medications typically used in the treatment of Parkinson's, L-DOPA and dopamine agonists, improve the early symptoms of the disease. As the disease progresses and dopaminergic neurons continue to be lost, the drugs eventually become ineffective while at the same time frequently producing a complication marked by involuntary writhing movements. In 2013 PD resulted in about 103,000 deaths globally, up from 44,000 deaths in 1990.
About ISC-hpNSC®
About International Stem Cell Corporation
To subscribe to receive ongoing corporate communications, please click on the following link: http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0
Safe harbor statement
Statements pertaining to anticipated developments, expected results and timing of clinical studies, potential applications of ISC-hpNSC® to other diseases, progress of research and development initiatives, and other opportunities for the company and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates,") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products (including clinical trial results that differ from expectations based on earlier studies), regulatory approvals, need and ability to obtain future capital, application of capital resources among competing uses, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the company's business, particularly those mentioned in the cautionary statements found in the company's Securities and Exchange Commission filings. The company disclaims any intent or obligation to update forward-looking statements.
http://health.einnews.com/article/329042037/8vjgpYKKyqbW9usc
No comments:
Post a Comment